All Blogs

Nov 19, 2024

The Society for Immunotherapy of Cancer i.e., SITC 2024 conference provided a comprehensive view into the latest innovations in cancer immunotherapy, including data on CAR T-cell therapies, cancer vaccines, bispecific and multispecific antibodies, along with next-generation cancer vaccines. Presentations from vario...

Nov 19, 2024

The 17th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, held in Madrid from October 29 to November 1, 2024, set the stage for groundbreaking updates in Alzheimer’s research, as pharmaceutical leaders presented their latest findings on novel therapies and cutting-edge clinical trials. With an ever-growing...

Nov 20, 2024

Medical radiation detection devices are not just safety tools; they are integral to maintaining the delicate balance between leveraging the benefits of radiation and minimizing its risks. With radiation playing a pivotal role in diagnosing and treating life-threatening conditions such as cancer, the need for precis...

Nov 19, 2024

FDA Approves AADC Deficiency Gene Therapy by PTC Therapeutics PTC Therapeutics, Inc. has secured FDA accelerated approval for KEBILIDI (eladocagene exuparvovec-tneq), marking a historic milestone as the first-ever gene therapy directly administered to the brain in the United States. This innovative therapy addre...

Nov 22, 2024

NK cell therapies have demonstrated significant clinical efficacy, with studies reporting response rates ranging from 40% to 80% in certain hematologic malignancies. As of recent data, several NK cell therapy candidates are in clinical trials, with notable successes including improved overall survival rates and red...

Nov 18, 2024

Parkinson’s disease is the second most common neurodegenerative disorder after Alzheimer’s disease. It affects about 10 million people worldwide. The average age of onset for Parkinson’s disease is around 60; however, approximately 10-15% of patients experience early-onset PD before the age of 50. In 2023, there...

Nov 15, 2024

Immunotherapy has revolutionized the treatment landscape for cancer, offering hope for patients who have exhausted traditional therapeutic options. In the ever-evolving field of immunotherapy, two emerging approaches—CAR-T cells and CAR-Exosome agents—are garnering attention for their potential to revolutionize the...

Nov 14, 2024

Caris Life Sciences Received FDA Approval for MI Cancer Seek™ as a Companion Diagnostic (CDx) Test  On November 6, 2024, Caris Life Sciences, a leading next-generation AI TechBio company and precision medicine pioneer, announced that the U.S. Food and Drug Administration (FDA) approved MI Cancer Seek™ for u...

Nov 13, 2024

In the fast-evolving world of healthcare, optimizing operating room (OR) efficiency is essential for improving patient outcomes, reducing hospital costs, and increasing operational throughput. Operating rooms, the heart of any hospital, have long been hubs of innovation; however, with today’s technological advancem...

Nov 12, 2024

FDA Approves Autolus's AUCATZYL for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia Autolus Therapeutics has achieved a significant milestone with FDA approval for AUCATZYL (obecabtagene autoleucel), a next-generation CAR T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic le...